Hematology

Epoetin alfa biosimilar shows promise in early study.

Empliciti combination decreased disease progression risk by 30%.

Reolysin plus bortezomib and dexamethasone treats patients with relapsed or refractory multiple myeloma.

Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide and dexamethasone.

Molecular mechanisms behind acute myeloid leukemia may offer a new target for drug development.

Novel drug shows promise in chronic lymphocytic leukemia and non-Hodgkin lymphoma refractory or resistant to current chemotherapies.

Daratumumab is a single agent for multiple myeloma in patients who previously received at least 3 lines of therapy.

Approval sought for Imbruvica combination for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Multiple myeloma comorbidities may contribute to the development of pulmonary hypertension.

Patients with cancer see a decline in employment, hours worked, individual income, and total family income following diagnosis.

Once-a-week treatment is the first oral proteasome inhibitor to reach late stage clinical development.

Terms like revolutionary or miracle cause confusion for readers.

Multiple myeloma therapeutic spending forecast to his $22.4 billion by 2023.

Blood test offers insight into how well a drug is working during the course of cancer treatment.

Malaria protein is able to attack more than 90 percent of all tumor types.

Clonogenic stem cells show heightened self-renewal and differentiation capacities in multiple myeloma.

Carfilzomib, pomalidomide, and dexamethasone regimen safe and well tolerated during recent study.

Research may improve the design of pharmaceuticals for leukemia and other types of cancer.

Test may help clinicians identify the best course of therapy for patients with Diffuse Large B-Cell Lymphoma.

Multiple myeloma disease development affected by pituitary tumor transforming gene.

Exercise following diagnosis may offer significant protection among cancer survivors.

Certain pesticide contaminants found to increase risk of multiple myeloma.

Just 5% of myeloma cases are in the first phase at diagnosis.

Families of children with cancer face food, housing, and energy insecurity.

BRD4 gene could be exploited in treatment of acute myeloid leukemia.